NeuroSense Therapeutics Ltd

NeuroSense Therapeutics CFO buys 200k shares amid PrimeC Phase 3 progress, signaling confidence in FDA‑cleared ALS therapy while noting cash limits and partnership needs.

NeuroSense insider deals reveal executive confidence in its ALS‑focused pipeline—highlighting milestone‑driven equity, potential market gains, and competitive edge.

Insider buying and warrants at NeuroSense Therapeutics signal leadership confidence, boosting prospects for PrimeC’s Phase‑3 success and future stock upside.